Back to results
US 10,370,714 B2Granted
Th-17 differentiation markers for rosacea and uses thereof
AssigneesGalderma Research & Development, Universitat Munster
InventorMartin Steinhoff
Life of this patent
Estimating the term…
Abstract
A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment.
Claims11
A method of detecting a level of gene expression of a marker for rosacea subtype I, subtype II, or subtype III in a patient, the method comprising:
- (a) obtaining a skin sample from a patient suspected of having rosacea subtype I, subtype II, or subtype III;
- (b) measuring gene expression of IL 26, and/or CCL20 in the skin sample;
- (c) comparing the gene expression of IL 26, and/or CCL20 in the skin sample against a level of gene expression of IL 26, and/or CCL20 in a control skin sample of a healthy individual.
A method for monitoring efficacy of a treatment intended for treating rosacea subtype I, subtype II, or subtype III, the method comprising:
- (a) administering a desired treatment to an individual identified as having one or more symptoms of rosacea subtype I, subtype II, or subtype III,
- (b) taking skin samples from the individual before, during, and/or after the administration,
- (c) comparing gene expression of IL-26, and/or CCL20, in the skin samples.
Dependencies are inferred from the claim text.